Pricing Log in Create free account
Friday 6 November 2026 Export DXCM’s income statement to Excel — free account

DexCom, Inc.

DXCM Healthcare Medical Devices

DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024.

Revenue
+11.2%
EPS
+0.58%
Free cash flow
−52.9%
Total debt
+0.31%

Quarter to September 2026, against a year earlier

79.50 4.96 −5.87%
Market cap
$31.5B
P/E
30.6×
Fwd P/E
31.8×
Dividend yield
—
F-score
8/9
Altman Z
6.43
Beneish M
−2.70
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

DexCom, Inc. 10-Q filed Jul 30, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 5:21 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Apr 30, 2026: 1 added · 12 modified; 8 with only figures updated

  1. Modified · Critical Accounting Estimates

    Overview of Financial Results The most important financial indicators that we use to assess our business are revenue, gross profit, operating income, net income, and operating cash flow. Key Highlights for the Three Months Ended March 31June 30, 2026 include the following: Revenue | Gross Profit | Operating Income | Net Income | Operating Cash Flow $1.191.31 billion | $750.3830.0 million | $255.3318.3 million | $199.5249.1 million | $525.6269.2 million up 1513% from the same period in 2025 | up 2720% from the same period in 2025 | up 9150% from the same period in 2025 | up 8939% from the same period in 2025 | up 186down 11% from the same period in 2025